-
Something wrong with this record ?
Treatment regimens and glycaemic outcomes in more than 100 000 children with type 1 diabetes (2013-22): a longitudinal analysis of data from paediatric diabetes registries
AT. Zimmermann, S. Lanzinger, SJ. Kummernes, NA. Lund-Blix, RW. Holl, E. Fröhlich-Reiterer, DM. Maahs, O. Ebekozien, S. Rompicherla, JT. Warner, S. Pons Perez, H. Robinson, ME. Craig, S. Johnson, K. Akesson, A. Thorén, K. Eeg-Olofsson, AG....
Language English Country England, Great Britain
Document type Journal Article
- MeSH
- Diabetes Mellitus, Type 1 * epidemiology blood drug therapy MeSH
- Child MeSH
- Glycated Hemoglobin * analysis MeSH
- Hypoglycemia epidemiology MeSH
- Hypoglycemic Agents * therapeutic use MeSH
- Infant MeSH
- Blood Glucose * analysis MeSH
- Humans MeSH
- Longitudinal Studies MeSH
- Adolescent MeSH
- Child, Preschool MeSH
- Registries * statistics & numerical data MeSH
- Glycemic Control statistics & numerical data methods MeSH
- Treatment Outcome MeSH
- Check Tag
- Child MeSH
- Infant MeSH
- Humans MeSH
- Adolescent MeSH
- Male MeSH
- Child, Preschool MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: Advances in paediatric type 1 diabetes management and increased use of diabetes technology have led to improvements in glycaemia, reduced risk of severe hypoglycaemia, and improved quality of life. Since 1993, progressively lower HbA1c targets have been set. The aim of this study was to perform a longitudinal analysis of HbA1c, treatment regimens, and acute complications between 2013 and 2022 using data from eight national and one international paediatric diabetes registries. METHODS: In this longitudinal analysis, we obtained data from the Australasian Diabetes Data Network, Czech National Childhood Diabetes Register, Danish Registry of Childhood and Adolescent Diabetes, Diabetes Prospective Follow-up Registry, Norwegian Childhood Diabetes Registry, England and Wales' National Paediatric Diabetes Audit, Swedish Childhood Diabetes Registry, T1D Exchange Quality Improvement Collaborative, and the SWEET initiative. All children (aged ≤18 years) with type 1 diabetes with a duration of longer than 3 months were included. Investigators compared data from 2013 to 2022; analyses performed on data were pre-defined and conducted separately by each respective registry. Data on demographics, HbA1c, treatment regimen, and event rates of diabetic ketoacidosis and severe hypoglycaemia were collected. ANOVA was performed to compare means between registries and years. Joinpoint regression analysis was used to study significant breakpoints in temporal trends. FINDINGS: In 2022, data were available for 109 494 children from the national registries and 35 590 from SWEET. Between 2013 and 2022, the aggregated mean HbA1c decreased from 8·2% (95% CI 8·1-8·3%; 66·5 mmol/mol [65·2-67·7]) to 7·6% (7·5-7·7; 59·4mmol/mol [58·2-60·5]), and the proportion of participants who had achieved HbA1c targets of less than 7% (<53 mmol/mol) increased from 19·0% to 38·8% (p<0·0001). In 2013, the aggregate event rate of severe hypoglycaemia rate was 3·0 events per 100 person-years (95% CI 2·0-4·9) compared with 1·7 events per 100 person-years (1·0-2·7) in 2022. In 2013, the aggregate event rate of diabetic ketoacidosis was 3·1 events per 100 person-years (95% CI 2·0-4·8) compared with 2·2 events per 100 person-years (1·4-3·4) in 2022. The proportion of participants with insulin pump use increased from 42·9% (95% CI 40·4-45·5) in 2013 to 60·2% (95% CI 57·9-62·6) in 2022 (mean difference 17·3% [13·8-20·7]; p<0·0001), and the proportion of participants using continuous glucose monitoring (CGM) increased from 18·7% (95% CI 9·5-28·0) in 2016 to 81·7% (73·0-90·4) in 2022 (mean difference 63·0% [50·3-75·7]; p<0·0001). INTERPRETATION: Between 2013 and 2022, glycaemic outcomes have improved, parallel to increased use of diabetes technology. Many children had HbA1c higher than the International Society for Pediatric and Adolescent Diabetes (ISPAD) 2022 target. Reassuringly, despite targeting lower HbA1c, severe hypoglycaemia event rates are decreasing. Even for children with type 1 diabetes who have access to specialised diabetes care and diabetes technology, further advances in diabetes management are required to assist with achieving ISPAD glycaemic targets. FUNDING: None. TRANSLATIONS: For the Norwegian, German, Czech, Danish and Swedish translations of the abstract see Supplementary Materials section.
Barbara Davis Center University of Colorado Aurora CO USA
Centre Hospitalier de Luxembourg Luxembourg City Luxembourg
Charles Perkins Centre Westmead University of Sydney Sydney NSW Australia
Department of Biomedical and Clinical Sciences Linköping University Linköping Sweden
Department of Clinical Medicine Aalborg University Gistrup Denmark
Department of Clinical Medicine University of Copenhagen Copenhagen Denmark
Department of Endocrinology Queensland Children's Hospital Brisbane QLD Australia
Department of Medicine Sahlgrenska University Hospital Gothenburg Sweden
Department of Paediatric and Adolescent Medicine Medical University of Graz Graz Austria
Department of Pediatrics and Adolescent Medicine Aalborg University Hospital Aalborg Denmark
Department of Pediatrics Haugesund Hospital Fonna Health Trust Haugesund Norway
Department of Pediatrics Ryhov County Hospital Jönköping Sweden
Division of Medicine Lyell McEwin Hospital Adelaide SA Australia
German Center for Diabetes Research Munich Neuherberg Munich Germany
Institute of Clinical Medicine Faculty of Medicine University of Oslo Oslo Norway
National Paediatric Diabetes Audit Noah's Ark Children's Hospital for Wales Cardiff UK
National Paediatric Diabetes Audit Royal College of Paediatrics and Child Health London UK
Oslo Diabetes Research Center Oslo Norway
Paediatrics and Child Health University of New South Wales Sydney NSW Australia
Royal College of Paediatrics and Child Health London UK
School of Medicine University of Mississippi Jackson MI USA
Steno Diabetes Center Copenhagen Herlev Denmark
Steno Diabetes Center North Denmark Aalborg University Hospital Aalborg Denmark
The Swedish National Diabetes Register Center of Registers Gothenburg Sweden
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25002859
- 003
- CZ-PrNML
- 005
- 20250206103918.0
- 007
- ta
- 008
- 250121s2025 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S2213-8587(24)00279-1 $2 doi
- 035 __
- $a (PubMed)39622257
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Zimmermann, Anthony T $u Division of Medicine, Lyell McEwin Hospital, Adelaide, SA, Australia. Electronic address: anthony.zimmermann@sa.gov.au
- 245 10
- $a Treatment regimens and glycaemic outcomes in more than 100 000 children with type 1 diabetes (2013-22): a longitudinal analysis of data from paediatric diabetes registries / $c AT. Zimmermann, S. Lanzinger, SJ. Kummernes, NA. Lund-Blix, RW. Holl, E. Fröhlich-Reiterer, DM. Maahs, O. Ebekozien, S. Rompicherla, JT. Warner, S. Pons Perez, H. Robinson, ME. Craig, S. Johnson, K. Akesson, A. Thorén, K. Eeg-Olofsson, AG. Ranjan, M. Madsen, M. Witsch, H. Bratke, GT. Alonso, Z. Sumnik, V. Neuman, O. Cinek, T. Skrivarhaug, J. Svensson
- 520 9_
- $a BACKGROUND: Advances in paediatric type 1 diabetes management and increased use of diabetes technology have led to improvements in glycaemia, reduced risk of severe hypoglycaemia, and improved quality of life. Since 1993, progressively lower HbA1c targets have been set. The aim of this study was to perform a longitudinal analysis of HbA1c, treatment regimens, and acute complications between 2013 and 2022 using data from eight national and one international paediatric diabetes registries. METHODS: In this longitudinal analysis, we obtained data from the Australasian Diabetes Data Network, Czech National Childhood Diabetes Register, Danish Registry of Childhood and Adolescent Diabetes, Diabetes Prospective Follow-up Registry, Norwegian Childhood Diabetes Registry, England and Wales' National Paediatric Diabetes Audit, Swedish Childhood Diabetes Registry, T1D Exchange Quality Improvement Collaborative, and the SWEET initiative. All children (aged ≤18 years) with type 1 diabetes with a duration of longer than 3 months were included. Investigators compared data from 2013 to 2022; analyses performed on data were pre-defined and conducted separately by each respective registry. Data on demographics, HbA1c, treatment regimen, and event rates of diabetic ketoacidosis and severe hypoglycaemia were collected. ANOVA was performed to compare means between registries and years. Joinpoint regression analysis was used to study significant breakpoints in temporal trends. FINDINGS: In 2022, data were available for 109 494 children from the national registries and 35 590 from SWEET. Between 2013 and 2022, the aggregated mean HbA1c decreased from 8·2% (95% CI 8·1-8·3%; 66·5 mmol/mol [65·2-67·7]) to 7·6% (7·5-7·7; 59·4mmol/mol [58·2-60·5]), and the proportion of participants who had achieved HbA1c targets of less than 7% (<53 mmol/mol) increased from 19·0% to 38·8% (p<0·0001). In 2013, the aggregate event rate of severe hypoglycaemia rate was 3·0 events per 100 person-years (95% CI 2·0-4·9) compared with 1·7 events per 100 person-years (1·0-2·7) in 2022. In 2013, the aggregate event rate of diabetic ketoacidosis was 3·1 events per 100 person-years (95% CI 2·0-4·8) compared with 2·2 events per 100 person-years (1·4-3·4) in 2022. The proportion of participants with insulin pump use increased from 42·9% (95% CI 40·4-45·5) in 2013 to 60·2% (95% CI 57·9-62·6) in 2022 (mean difference 17·3% [13·8-20·7]; p<0·0001), and the proportion of participants using continuous glucose monitoring (CGM) increased from 18·7% (95% CI 9·5-28·0) in 2016 to 81·7% (73·0-90·4) in 2022 (mean difference 63·0% [50·3-75·7]; p<0·0001). INTERPRETATION: Between 2013 and 2022, glycaemic outcomes have improved, parallel to increased use of diabetes technology. Many children had HbA1c higher than the International Society for Pediatric and Adolescent Diabetes (ISPAD) 2022 target. Reassuringly, despite targeting lower HbA1c, severe hypoglycaemia event rates are decreasing. Even for children with type 1 diabetes who have access to specialised diabetes care and diabetes technology, further advances in diabetes management are required to assist with achieving ISPAD glycaemic targets. FUNDING: None. TRANSLATIONS: For the Norwegian, German, Czech, Danish and Swedish translations of the abstract see Supplementary Materials section.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a diabetes mellitus 1. typu $x epidemiologie $x krev $x farmakoterapie $7 D003922
- 650 12
- $a registrace $x statistika a číselné údaje $7 D012042
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a longitudinální studie $7 D008137
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a předškolní dítě $7 D002675
- 650 12
- $a glykovaný hemoglobin $x analýza $7 D006442
- 650 12
- $a hypoglykemika $x terapeutické užití $7 D007004
- 650 12
- $a krevní glukóza $x analýza $7 D001786
- 650 _2
- $a hypoglykemie $x epidemiologie $7 D007003
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a kojenec $7 D007223
- 650 _2
- $a regulace glykemie $x statistika a číselné údaje $x metody $7 D000085002
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Lanzinger, Stefanie $u Institute of Epidemiology and Medical Biometry, Computer Assisted Quality Management, Ulm University, Ulm, Germany; German Center for Diabetes Research, Munich-Neuherberg, Munich, Germany
- 700 1_
- $a Kummernes, Siv Janne $u The Norwegian Childhood Diabetes Registry, Division of Childhood and Adolescent Medicine, Oslo University Hospital, Oslo, Norway
- 700 1_
- $a Lund-Blix, Nicolai A $u The Norwegian Childhood Diabetes Registry, Division of Childhood and Adolescent Medicine, Oslo University Hospital, Oslo, Norway
- 700 1_
- $a Holl, Reinhard W $u Institute of Epidemiology and Medical Biometry, Computer Assisted Quality Management, Ulm University, Ulm, Germany; German Center for Diabetes Research, Munich-Neuherberg, Munich, Germany
- 700 1_
- $a Fröhlich-Reiterer, Elke $u Department of Paediatric and Adolescent Medicine, Medical University of Graz, Graz, Austria
- 700 1_
- $a Maahs, David M $u Department of Pediatrics, Division of Endocrinology, Stanford University School of Medicine, California, CA, USA
- 700 1_
- $a Ebekozien, Osagie $u T1D Exchange, Boston, MA, USA; School of Medicine, University of Mississippi, Jackson, MI, USA
- 700 1_
- $a Rompicherla, Saketh $u T1D Exchange, Boston, MA, USA
- 700 1_
- $a Warner, Justin T $u National Paediatric Diabetes Audit, Noah's Ark Children's Hospital for Wales, Cardiff, UK
- 700 1_
- $a Pons Perez, Saira $u National Paediatric Diabetes Audit, Royal College of Paediatrics and Child Health, London, UK
- 700 1_
- $a Robinson, Holly $u Royal College of Paediatrics and Child Health, London, UK
- 700 1_
- $a Craig, Maria E $u Paediatrics and Child Health, University of New South Wales, Sydney, NSW, Australia; Charles Perkins Centre Westmead, University of Sydney, Sydney, NSW, Australia
- 700 1_
- $a Johnson, Stephanie $u Department of Endocrinology, Queensland Children's Hospital, Brisbane, QLD, Australia
- 700 1_
- $a Akesson, Karin $u The Swedish National Diabetes Register, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden; Department of Pediatrics, Ryhov County Hospital, Jönköping, Sweden; The Swedish National Diabetes Register, Center of Registers, Gothenburg, Sweden
- 700 1_
- $a Thorén, Alexander $u The Swedish National Diabetes Register, Center of Registers, Gothenburg, Sweden
- 700 1_
- $a Eeg-Olofsson, Katarina $u The Swedish National Diabetes Register, Center of Registers, Gothenburg, Sweden; Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden
- 700 1_
- $a Ranjan, Ajenthen G $u Steno Diabetes Center Copenhagen, Herlev, Denmark
- 700 1_
- $a Madsen, Mette $u Steno Diabetes Center North Denmark, Aalborg University Hospital, Aalborg, Denmark; Department of Pediatrics and Adolescent Medicine, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Aalborg University, Gistrup, Denmark
- 700 1_
- $a Witsch, Michael $u Centre Hospitalier de Luxembourg, Luxembourg City, Luxembourg
- 700 1_
- $a Bratke, Heiko $u Department of Pediatrics, Haugesund Hospital, Fonna Health Trust, Haugesund, Norway
- 700 1_
- $a Alonso, G Todd $u Barbara Davis Center, University of Colorado, Aurora, CO, USA
- 700 1_
- $a Sumnik, Zdenek $u Department of Pediatrics, 2nd Faculty of Medicine, Motol University Hospital, Charles University, Prague, Czechia
- 700 1_
- $a Neuman, Vit $u Department of Pediatrics, 2nd Faculty of Medicine, Motol University Hospital, Charles University, Prague, Czechia
- 700 1_
- $a Cinek, Ondrej $u Department of Pediatrics, 2nd Faculty of Medicine, Motol University Hospital, Charles University, Prague, Czechia
- 700 1_
- $a Skrivarhaug, Torild $u The Norwegian Childhood Diabetes Registry, Division of Childhood and Adolescent Medicine, Oslo University Hospital, Oslo, Norway; Oslo Diabetes Research Center, Oslo, Norway; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
- 700 1_
- $a Svensson, Jannet $u Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden; Steno Diabetes Center Copenhagen, Herlev, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
- 773 0_
- $w MED00186388 $t The lancet. Diabetes & endocrinology $x 2213-8595 $g Roč. 13, č. 1 (2025), s. 47-56
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39622257 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250121 $b ABA008
- 991 __
- $a 20250206103913 $b ABA008
- 999 __
- $a ok $b bmc $g 2262951 $s 1238866
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 13 $c 1 $d 47-56 $e 20241129 $i 2213-8595 $m The lancet. Diabetes & endocrinology $n Lancet Diabetes Endocrinol $x MED00186388
- LZP __
- $a Pubmed-20250121
